Vor Biopharma (VOR) Stock Forecast & Price Target

$0.87 -0.02 (-2.19%)

(As of 12/20/2024 05:31 PM ET)

Vor Biopharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Vor Biopharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for VOR.

Consensus Price Target

$11.36
1,209.48% Upside

According to the 7 analysts' twelve-month price targets for Vor Biopharma, the average price target is $11.36. The highest price target for VOR is $17.50, while the lowest price target for VOR is $3.00. The average price target represents a forecasted upside of 1,209.48% from the current price of $0.87.

Get the Latest News and Ratings for VOR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vor Biopharma and its competitors.

VOR Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.36	$11.36	$10.92	$15.19
Forecasted Upside	1,209.48% Upside	1,326.60% Upside	1,112.96% Upside	670.94% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

VOR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VOR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vor Biopharma Stock vs. The Competition

Type	Vor Biopharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	1,209.48% Upside	25,828.93% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent VOR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
12/10/2024	JMP Securities 2 of 5 stars	Reiterated Rating	Market Outperform ➝ Market Outperform	$12.00 ➝ $12.00	+1,099.99%
12/10/2024	HC Wainwright 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$17.50 ➝ $17.50	+1,649.98%
12/9/2024	Wedbush 4 of 5 stars	Reiterated Rating	Outperform	$11.00	+957.68%
11/8/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$22.00 ➝ $14.00	+1,578.44%
8/14/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$10.00 ➝ $3.00	+256.55%
5/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $10.00	+461.80%
Get the Latest News and Ratings for VOR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.
3/21/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$15.00 ➝ $12.00	+545.16%
3/24/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy	$17.00 ➝ $16.00	+171.19%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:52 AM ET.

VOR Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Vor Biopharma is $11.36, with a high forecast of $17.50 and a low forecast of $3.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vor Biopharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VOR shares.
: According to analysts, Vor Biopharma's stock has a predicted upside of 1,209.48% based on their 12-month stock forecasts.
: Vor Biopharma has been rated by research analysts at HC Wainwright, JMP Securities, Robert W. Baird, and Wedbush in the past 90 days.
: Analysts like Vor Biopharma more than other "medical" companies. The consensus rating for Vor Biopharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VOR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

This page (NYSE:VOR) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Stock Forecast & Price Target